KBC Securities - ONWARD MEDICAL NV (ONWD) Onward Medical Takeaways from Up-LIFT panel discussion

Report

KBC Securities

Thomas Vranken

Onward Medical Takeaways from Up-LIFT panel discussion

Yesterday, Onward held a webcast to discuss its Q1 results and hosted a panel to discuss the recently published Up-LIFT trial data in Nature (Moritz et al., 2024). Beyond our note highlighting the results of the study, we have compiled our key takeaways from the discussion.

24/05/2024 1 EN

Underlying

ONWARD MEDICAL NV

See profile

NL0015000HT4 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

GlobeNewsWire

ONWARD® Medical Announces Participation in Stifel European Healthcare Summit

ONWARD® Medical Announces Participation in Stifel European Healthcare Summit CEO Dave Marver will meet with investors to discuss the Company’s achievements and upcoming milestones EINDHOVEN, the Netherlands, June 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its participation in the Stifel European Healthcare Summit in Lyon, France from June 25-27th. CEO Dave Marver will mee...

6h / 5m 6h / 5m 1 EN

GlobeNewsWire

ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference

ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation EINDHOVEN, the Netherlands, June 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that the Company will be highlighted in a main stage keynote at HLTH Europe, a premier event for digit...

June 18, 2024 June 18, 2024 1 EN

GlobeNewsWire

ONWARD® Medical Announces Results of Annual General Meeting of Shareholders

ONWARD® Medical Announces Results of Annual General Meeting of Shareholders THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, the Netherlands, June 13, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces all proposed resolutions at its...

June 13, 2024 June 13, 2024 1 EN

Morning Notes : ARGX BB, BAR BB, DIE BB, ALFEN NA

: ARGX BB, BAR BB, DIE BB, ALFEN NA

4h / 34m 4h / 34m 1 EN

Michiel Declercq

Michiel Declercq

D'Ieteren Key highlights from the PHE strategy day & model update

Yesterday, PHE held a strategy day at its Logisteo distribution centre in Reau France, giving investors the opportunity to meet with PHE's management (CEO, CFO & COO) for the first time since the acquisition by D'Ieteren in 2022. As expected, no new financial targets were disclosed. However, during the presentation, the underlying growth drivers for the business were reiterated. Below, we summarize the key highlights. Additionally, we also slightly adjusted our D'Ieteren group estimates following the 1Q24 update (end-May). Although we have slightly tweaked our estimates to the downside due to ...

5h / 3m 5h / 3m 1 EN

Wim Hoste

Wim Hoste

Solvay Feedback Performance Chemicals webinar

Below are the highlights from the Performance Chemicals webinar which was held this morning. After the recent spun off of Syensqo, Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company will be managed with a conservative financial approach, favouring dividends over aggressive growth and operating with a solid balance sheet (1.4x leverage). The stable to growing dividend flow implies a solid 7% dividend yield. Other valuation ratios also look attractive and prompt us to reiterate our BUY rating and € 40 target price.

June 25, 2024 June 25, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Onward Medical Takeaways from Up-LIFT panel discussion

We are a financial services provider for several types of professional clients, each with distinct needs.

ONWARD® Medical Announces Participation in Stifel European Healthcare Summit

ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference

ONWARD® Medical Announces Results of Annual General Meeting of Shareholders

Morning Notes : ARGX BB, BAR BB, DIE BB, ALFEN NA

D'Ieteren Key highlights from the PHE strategy day & model update

Solvay Feedback Performance Chemicals webinar

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe